Shannon C - Search Results

1

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.

Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. Lindeman GJ, et al. Among authors: shannon c. Clin Cancer Res. 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. Clin Cancer Res. 2022. PMID: 35583555 Free PMC article. Clinical Trial.

2

Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.

Shannon C, Kirk J, Barnetson R, Evans J, Schnitzler M, Quinn M, Hacker N, Crandon A, Harnett P. Shannon C, et al. Clin Cancer Res. 2003 Apr;9(4):1387-92. Clin Cancer Res. 2003. PMID: 12684409

3

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.

Chan A, Shannon C, de Boer R, Baron-Hay S, Redfern A, Bauwens A, Craft P, Webb S, Townsend A, Kotasek D. Chan A, et al. Among authors: shannon c. Asia Pac J Clin Oncol. 2014 Dec;10(4):368-75. doi: 10.1111/ajco.12292. Epub 2014 Oct 28. Asia Pac J Clin Oncol. 2014. PMID: 25351929 Clinical Trial.

4

Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.

Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, Seidl B, Gibbons K, Pyke C, Shannon C, Woodward N, Armes JE. Snell CE, et al. Among authors: shannon c. J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17. J Clin Pathol. 2017. PMID: 28416639

5

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.

Snell CE, Gough M, Liu C, Middleton K, Pyke C, Shannon C, Woodward N, Hickey TE, Armes JE, Tilley WD. Snell CE, et al. Among authors: shannon c. Br J Cancer. 2018 Nov;119(11):1316-1325. doi: 10.1038/s41416-018-0331-3. Epub 2018 Nov 9. Br J Cancer. 2018. PMID: 30410061 Free PMC article.

6

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.

Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Shannon C, et al. Ann Oncol. 2001 Jul;12(7):947-52. doi: 10.1023/a:1011186104428. Ann Oncol. 2001. PMID: 11521800 Free article.

7

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: shannon cm. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.

8

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, Spurdle A, Barnes E, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Andrews J, Stockler MR, Mileshkin L; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Antill Y, et al. Among authors: shannon c. J Immunother Cancer. 2021 Jun;9(6):e002255. doi: 10.1136/jitc-2020-002255. J Immunother Cancer. 2021. PMID: 34103352 Free PMC article. Clinical Trial.

9

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.

Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J. Friedlander M, et al. Among authors: shannon c. Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636. Asia Pac J Clin Oncol. 2016. PMID: 27917619 Review.

10

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib.

Friedlander M, Shannon C, Goh J, Scott C, Mileshkin L. Friedlander M, et al. Among authors: shannon c. Asia Pac J Clin Oncol. 2018 Dec;14(6):459-464. doi: 10.1111/ajco.13104. Epub 2018 Nov 26. Asia Pac J Clin Oncol. 2018. PMID: 30479036

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

629 results

Search Page